All articles by Ellen Daniel

  1. FDA names and shames companies inhibiting generics manufacturing

    The US Food and Drugs Administration (FDA) has released a list of pharmaceutical companies it believes are making it harder…
    Read More…

    23 May
  2. Nohla completes Series B financing for off-the-shelf cell therapies

    Cell therapy developer Nohla Therapeutics has announced the closing of a $45m Series B financing. In this round, Fidelity Management…
    Read More…

    21 May
  3. US doctors propose universal health care to fix ‘dysfunctional’ system

    A group of 21 doctors from the US and Canada has published a proposal aimed at ensuring access to ‘safe,…
    Read More…

    17 May
  4. Kite to open Netherlands cell therapy manufacturing facility

    Kite Therapeutics, a subsidiary of Gilead Sciences, has announced it has leased a facility in the Netherlands to engineer cell…
    Read More…

    17 May
  5. US Health Secretary proposes changes to Medicare plans

    US Health and Human Services secretary Alex Azar has announced changes to Medicare Part B in a bid to lower…
    Read More…

    16 May
  6. Eli Lilly drug shows positive results in cluster headache patients

    Eli Lilly has announced that migraine drug galcanezumab met its primary endpoints in a Phase III study in patients with…
    Read More…

    16 May
  7. Trump’s drug price plans: a ‘sugar-coated nothing pill’?

    In a long-awaited speech delivered at the White House Rose Garden on Friday, Trump launched what he described as ‘the…
    Read More…

    15 May
  8. Medigene and Bluebird Bio to expand cell therapy oncology partnership

    German biotechnology company Medigene has announced it is expanding its strategic alliance with gene and cell therapies experts Bluebird Bio…
    Read More…

    15 May
  9. AstraZeneca drug fails to meet primary endpoints in COPD trial

    AstraZeneca and MedImmune, its global biologics research and development arm, have announced that respiratory drug Fasenra failed to meet primary…
    Read More…

    11 May
  10. Roche cancer drug Tecentriq fails in Phase III trial

    Roche has announced that checkpoint inhibitor Tecentriq (atezolizumab) in combination with Cotellic (cobimetinib) failed to meet its primary endpoint of…
    Read More…

    11 May